Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Brendan D. Parent, Connor J. Hennessey, Alexander C. Jordan, Micaela Morgado, Shatavisha Dasgupta, Giselle A. Uribe, A.K.M. Shamsuddin and Guang-Yu Yang, Kevin S. Kapner, Felix P. Hambitzer, Qiang Li, Hanrong Feng, Jacob Geisberg, Junning Wang, Kyle E. Evans, Hengyu Lyu, Aislyn Schalck, Ningping Feng, Anastasia M. Lopez, Christopher A. Bristow, Michael P. Kim, Kimal Rajapakshe, Vahid Bahrambeigi, Jennifer A. Roth, Kavita S. Garg, Paola A. Guerrero, Ben Z. Stanger, Simona Cristea, Scott W. Lowe, Timour Baslan, Eliezer M. Van Allen, Joseph D. Mancias, Emily Chan, Abraham Anderson, Yuliya V. Katlinskaya, Alex K. Shalek, David S. Hong, Shubham Pant, Jill Hallin, Kenna Anderes, Peter Olson, Timothy P. Heffernan, Seema Chugh, James G. Christensen, Anirban Maitra, Brian M. Wolpin, Srivatsan Raghavan, Jonathan A. Nowak, Peter Winter, Stephanie K. Dougan, Andrew J. Aguirre
Cited by 0Open Access
Abstract
<p>Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.</p>
Related Papers
No related papers found
Powered by citation graph analysis